KDM1A and acute lymphoblastic leukemia: We found that the combination of catalytic LSD1 inhibitor (GSK-LSD1i, 0–600 nM) with Ruxolitinib (0–600 nM) was not effective for the in vitro synergistic killing of the human LOUCY ETP-ALL cells (Fig. 6A) within a 72-h period, and this held true at high drug concentrations (Fig. S8A) or using ORY-1001 another catalytic LSD1 inhibitor (Fig. S8B).